ATLASATLAS fair value
ATLAS has no fair value for this stock today.
OliX PharmaceuticalsInc (226950.KQ)
OliX PharmaceuticalsInc stock price today, ATLAS forecast and fair value
Healthcare · Biotechnology · KOSDAQ · South Korea
₩96,100▼ -6.97%
Prices as of Oct 26, 2026 · KRW
Chance of rising in 1 month
44%
that it ends higher than today in 21 sessions
0%coin flip 50%100%
This is just the summary. See everything on OliX PharmaceuticalsInc in ATLAS
ATLAS's own quantitative analysis, all in one place.
- Simulation and expected rangeThousands of simulated scenarios: how far the price could rise or fall.
- Officers and shareholdersWho runs the company and which funds hold its shares.
- Customer and supplier mapWho it does business with, from its own filings.
- ATLAS builds your portfolioAnswer a short test and get portfolios that fit you.
- AlertsWe let you know when something changes in your stocks.
See everything included
- Valuation and financialsFair value step by step, quarterly accounts and upcoming events.
- NewsThe latest on the company, in one place.
- Crisis simulatorHow your portfolio would do in a crash like 2008.
- Practice risk-free$10,000 in virtual money to invest at real prices.
- Global screenerSearch US stocks and stocks from 47 countries with filters.
On OliX PharmaceuticalsInc
- Simulation and expected rangeThousands of simulated scenarios: how far the price could rise or fall.
- Officers and shareholdersWho runs the company and which funds hold its shares.
- Customer and supplier mapWho it does business with, from its own filings.
- Valuation and financialsFair value step by step, quarterly accounts and upcoming events.
- NewsThe latest on the company, in one place.
And for you
- ATLAS builds your portfolioAnswer a short test and get portfolios that fit you.
- AlertsWe let you know when something changes in your stocks.
- Crisis simulatorHow your portfolio would do in a crash like 2008.
- Practice risk-free$10,000 in virtual money to invest at real prices.
- Global screenerSearch US stocks and stocks from 47 countries with filters.
Plans from €3.99 a month.
ATLAS's model gives OliX PharmaceuticalsInc a 44% chance of finishing higher a month from now (21 trading sessions) than today: somewhat worse than a coin flip.
In half of the simulated outcomes the price ends between ₩77,960 and ₩110,188; in 9 out of 10, between ₩57,369 and ₩149,737. Estimated annual volatility is 102%.
Price, last 12 months (weekly close)
Key numbers
- Market cap
- ₩1.9T
- Market cap (USD)
- $1.5B
- 52-week high
- ₩217,000
- 52-week low
- ₩84,300
- Revenue (12 months)
- ₩13.6B
- Gross margin
- 97.6%
- Net margin
- -102.9%
- Beta
- 0.40
What this means
ATLAS does not publish a fair value for 226950.KQ right now, but it does show its odds of rising: somewhat worse than a coin flip.
Over the last 52 weeks 226950.KQ has traded between ₩84,300 and ₩217,000. Today it is 55.7% below that high and 14% above its low.
Its beta is 0.40: it tends to move less than the market.
About the company
OliX Pharmaceuticals, Inc., a clinical stage pharmaceutical company, focuses on developing RNA interference (RNAi) therapeutics for dermal, ophthalmic, and pulmonary diseases.
Want to see everything about OliX PharmaceuticalsInc?
Get started →Plans from €3.99 a month.
Comparable companies
Other companies in the same line of business:
Frequently asked questions
What does OliX PharmaceuticalsInc do?
OliX Pharmaceuticals, Inc., a clinical stage pharmaceutical company, focuses on developing RNA interference (RNAi) therapeutics for dermal, ophthalmic, and pulmonary diseases.
What is the chance 226950.KQ goes up next month?
44%: somewhat worse than a coin flip. In half of the simulated outcomes, 226950.KQ ends the month between ₩77,960 and ₩110,188.
How big is OliX PharmaceuticalsInc and what is its P/E ratio?
OliX PharmaceuticalsInc's market capitalization is ₩1.9T. We do not show a P/E because it has no positive earnings to base one on.
How volatile is 226950.KQ?
ATLAS estimates annual volatility at 102%. In a typical month, half of the outcomes end between ₩77,960 and ₩110,188.
Not investment advice. ATLAS estimates are produced by statistical models from public data; they can be wrong and past performance does not predict future results. Consider your own situation before investing. Disclaimer